Browse the evidence

Tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% for 5 mg, -4.63% for 10 mg, and -5.93% for 15 mg.

Tirzepatide may help in managing cholesterol levels in patients.

Tirzepatide treatment led to increased HDL cholesterol levels and decreased LDL cholesterol and triglyceride levels.

Tirzepatide may improve overall lipid profiles in patients.

Semaglutide improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) by +7.6 points in women and +7.5 points in men.

Semaglutide can be considered effective for improving heart failure symptoms in both men and women.

Longer daytime napping was associated with higher abdominal obesity prevalence (e.g., ≥1 hours: AOR, 1.39; 95% CI, 1.31-1.47).

Reducing the duration of daytime naps may help lower the risk of abdominal obesity.

Weight loss correlated with significant decreases in leptin and favorable modulation of inflammatory cytokines and lipid profiles.

Weight loss may improve metabolic health markers in breast cancer survivors.

Patients treated with semaglutide 2.4 mg had lower rates of all-cause death compared to placebo (HR: 0.81; 95% CI: 0.71-0.93).

Semaglutide may be an effective treatment for reducing overall mortality in patients with cardiovascular disease.

Tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduces Obstructive Sleep Apnea severity (AHI) and improves cardiometabolic biomarkers in patients with moderate-to-severe OSA and obesity, leading to FDA approval for this indication.

If you have moderate-to-severe sleep apnea and obesity, ask your doctor about tirzepatide. It is an FDA-approved treatment that reduces breathing interruptions during sleep and improves heart health markers. It requires weekly injections and lifestyle counseling, but offers a viable alternative or adjunct to CPAP for those struggling with adherence or residual symptoms.

Patients treated with GLP-1 RAs experienced a lower occurrence of sight-threatening complications, including blindness (HR, 0.77; 95% CI, 0.73-0.82).

GLP-1 RAs may help reduce the risk of severe ocular complications in T2D patients.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative wound dehiscence (RR: 0.711; P = 0.001).

GLP-1 RA may be beneficial in reducing wound complications post-surgery.

Long-acting amylin analogues have beneficial effects on body weight in obesity.

Long-acting amylin analogues may be considered as a treatment option for obesity.

Cagrilintide, a novel amylin analogue, shows promising body weight reducing effects.

Cagrilintide may be an effective treatment for weight loss, especially when combined with other therapies.

The majority of studies reported %FFML exceeding 25%.

Most patients on GLP-1RAs may experience a significant proportion of weight loss from fat-free mass.

GLP-1RA therapy can reduce the risk of cardiovascular disease (CVD) in high-risk individuals with type 2 diabetes (T2D).

Practitioners should consider GLP-1RA therapy for patients with T2D who are at high risk for cardiovascular disease.

A growing number of new agents acting on incretin hormones are becoming available for clinical practice.

Clinicians should stay informed about new pharmacological options for treating obesity and T2DM.

Preoperative discontinuation of semaglutide for > 21 days results in RGC similar to non-semaglutide users.

Practitioners should advise patients to discontinue semaglutide well in advance of procedures to reduce RGC risk.

The presence of ongoing digestive symptoms is significantly associated with increased RGC in semaglutide users.

Clinicians should monitor digestive symptoms in patients using semaglutide to assess RGC risk.

GLP-1 RA use was associated with reduced headaches (RR, 0.45; 95% CI, 0.35-0.58; P < .001).

GLP-1 RAs may help alleviate headache symptoms in IIH patients.

Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight.

Tirzepatide may be an effective treatment option for improving blood sugar levels and reducing weight in patients with type 2 diabetes.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduced the risk of any cardiovascular event in overweight or obese adults without diabetes.

GLP-1 RA can be considered for reducing cardiovascular risk in overweight or obese patients without diabetes.

GLP-1 RA treatment was associated with a significantly lower risk of all-cause mortality (hazard ratio 0.23; 95% confidence interval 0.15-0.34).

GLP-1 RAs may significantly reduce the risk of death in obese individuals without T2D.

GLP-1 RAs were associated with a lower risk of several cardiovascular complications, including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke, and atrial fibrillation.

GLP-1 RAs may help reduce the risk of serious cardiovascular issues in obese patients without T2D.

Injectable subcutaneous medications like semaglutide are gaining popularity for weight loss.

Practitioners should be aware of the increasing use of these medications for weight loss.

Retatrutide (LY3437943) is relatively safe and supports once-weekly dosing.

Practitioners can consider retatrutide as a potentially safe option for treatment with a convenient dosing schedule.

Retatrutide may be superior to dulaglutide in reducing plasma glucose and body weight.

Practitioners may consider retatrutide as a potentially more effective option than dulaglutide for managing diabetes.